X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Aventis Pharma: Strategy paying off - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 21, 2003

    Aventis Pharma: Strategy paying off

    Aventis Pharma announced its 3QFY04 results last week. While the company has reported a marginal 2% growth in the topline, operating efficiencies have helped it record a sharp 57% rise in bottomline. For 9mFY04 also, the company has reported a 6% and 54% growth in net sales and net profit respectively. In this context, let us take a brief look at the company’s performance.

    Results at a glance…
    (Rs m) 3QFY03 3QFY04 Change 9mFY03 9mFY04 Change
    Net Sales 1,592 1,628 2.3% 4,573 4,828 5.6%
    Other Income 31 61 96.8% 73 129 76.7%
    Expenditure 1,328 1,264 -4.8% 3,867 3,891 0.6%
    Operating Profit (EBDIT) 264 364 37.9% 706 937 32.7%
    Operating Profit Margin (%) 16.6% 22.4%   15.4% 19.4%  
    Interest 1 0   4 0  
    Depreciation 38 38 0.0% 113 118 4.4%
    Profit before Tax 256 387 51.2% 662 948 43.2%
    Extraordinary income -5 -5   -4 55  
    Tax 85 121 42.4% 215 320 48.8%
    Profit after Tax/(Loss) 166 261 57.2% 443 683 54.2%
    Net profit margin (%) 10.4% 16.0%   9.7% 14.1%  
    No. of Shares (m) 23 23   23 23  
    Earnings per share (Rs)* 28.9 45.4   25.7 39.6  
    P/E (x)   11.2     12.8  

    Aventis Pharma’s aggressive marketing strategy has helped it record a 7% growth in domestic sales during 3QFY03. The growth was fuelled by the good performance recorded by its strategic brands. Cardace (40%), Targocid (29%), Amarly (23%) and Clexane (17%) recorded impressive growth during the quarter. Among other major products, Combiflam (18% growth), Avil (10%) and Soframycin (9%) also continued to maintain leadership position in their respective segments. However, a 26% drop in export revenues stunted this growth. This was primarily on account of a drop in the overseas demand. Also, last year’s September quarter was exceptionally good for exports (34% growth over 3QFY02).

    Cost break-up
    (Rs m) 3QFY03 3QFY04 % Change 9mFY03 9mFY04 % Change
    Raw material 886 830 -6% 2,425 2,443 1%
    Staff cost 119 133 12% 383 407 6%
    Others 323 301 -7% 1,059 1,041 -2%
    Total Expenditure 1,328 1,264 -5% 3,867 3,891 1%

    Despite flat growth in the topline, Aventis Pharma managed to improve its operating efficiency resulting in a 5.8 percentage points improvement in operating margins. This was primarily on account of a drop in the raw material cost as a percentage of sales from 56% in 3QFY03 to 51% in 3QFY04. Other income increased due to higher interest and dividend income. Thus, higher operating margins and a sharp increase in the net margins have helped the company record a 57% rise in net profits.

    Continuing with its strategy of aggressive new product launches from its parent’s product portfolio, Aventis Pharma launched ‘Lantus’, world’s only 24-hour basal insulin in the anti – diabetics segment. Although, the company has separately disclosed Lantus’s performance in the current period, we expect it to be a top performer given its global success. ‘Lantus’ is likely to be one of the major growth drivers for the company going forward.

    At Rs 506, Aventis Pharma is trading at a P/E of 13x its 9mFY04 earnings. Given the company's aggressive new product launches and the resultant new product portfolio, declining DPCO cover and focus on lifestyle segments, we remain positive about the long-term prospects of the company. However, although Aventis Pharma has been successfully charging a premium for its products, the sustainability of the same in view of the rising competition in the domestic market remains a concern as this could put pressure on its margins. For more on Aventis, view the Research Report

     

     

    Equitymaster requests your view! Post a comment on "Aventis Pharma: Strategy paying off". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SANOFI INDIA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK SANOFI INDIA

    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SANOFI INDIA 5-YR ANALYSIS

    Detailed Financial Information With Charts

    COMPARE SANOFI INDIA WITH

    MARKET STATS